ARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

ARS Pharmaceuticals

13/08/2026 22:00

ARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -46 cents.  The mean expectation of four analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -61 cents to -36 cents per share.
Revenue rose 114.2% to $33.66 million from a year ago; analysts expected $31.32 million. 
ARS Pharmaceuticals Inc's reported EPS for the quarter was a loss of 63 cents​.
The company reported a quarterly loss of $62.34 million.
ARS Pharmaceuticals Inc shares had fallen by 24.5% this quarter and lost 48.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 14% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.00, about 80.5% above its last closing price of $6.05
This summary was machine generated from LSEG data August 13 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.49
-0.63
Missed
Mar. 31 2026 
-0.53
-0.61
Missed
Dec. 31 2025 
-0.44
-0.42
Beat
Sep. 30 2025 
-0.47
-0.52
Missed